>>Signaling Pathways>> DNA Damage/DNA Repair>> CDK>>(rel)-MC180295

(rel)-MC180295 (Synonyms: (rel)-MC180295)

Catalog No.GC34124

(rel)-MC180295((rel)-(rel)-MC180295)는 IC50이 5nM이고 다른 CDK에 비해 CDK9에 대해 최소 22배 더 선택적인 강력하고 선택적인 CDK9-사이클린 T1 억제제입니다. (rel)-MC180295는 또한 GSK-3α를 억제하고; 및 GSK-3β (rel)-MC180295((rel)-(rel)-MC180295)는 강력한 항종양 효과가 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

(rel)-MC180295 Chemical Structure

Cas No.: 2237942-08-2

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$218.00
재고 있음
5mg
US$198.00
재고 있음
10mg
US$320.00
재고 있음
50mg
US$1,053.00
재고 있음
100mg
US$1,477.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(rel)-MC180295 is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. (rel)-MC180295 also inhibits GSK-3α and GSK-3β. (rel)-MC180295 has potent anti-tumor effect[1].

(rel)-MC180295 (MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs, such as CDK1-Cyclin B (IC50, 138 nM), CDK2-Cyclin A (IC50, 233 nM), CDK2-Cyclin E (IC50, 367 nM), CDK3-Cyclin E (IC50, 399 nM), CDK4-Cyclin D (IC50, 112 nM), CDK5-P35 (IC50, 159 nM), CDK5-P25 (IC50, 186 nM), CDK6-Cyclin D3 (IC50, 712 nM), and CDK7-CycH/MAT1 (IC50, 555 nM). (rel)-MC180295 also inhibits GSK-3α and GSK-3β[1].(rel)-MC180295 (500 nM) reactivates epigenetically silenced genes by targeting CDK9 without affecting DNA methylation[1].(rel)-MC180295 (0.1 μM) inhibits the proliferation in cancer cells[1].

(rel)-MC180295 (MC180295; 20 mg/kg, i.p., qod) inhibits significant anti-tumor activity in mice bearing SW48 cells, shows no inhibitory activity against human T cell growth in vivo[1].

[1]. Zhang H, et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 2018 Nov 15;175(5):1244-1258.e26.

리뷰

Review for (rel)-MC180295

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (rel)-MC180295

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.